Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE M VENEREO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1144299009
CMS profile
324488
Location
DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$95.63

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $95.63 5

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $68.88 4
Boehringer Ingelheim Pharmaceuticals, Inc. $26.75 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE M VENEREO

NPI 1144299009 · CMS profile ID 324488

Allopathic & Osteopathic Physicians / Internal Medicine

DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $95.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $13.8808/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921203 CMS
Janssen Pharmaceuticals, Inc $17.8705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921205 CMS
Janssen Pharmaceuticals, Inc $17.8705/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921201 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.7503/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763507670 CMS
Janssen Pharmaceuticals, Inc $19.2602/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921207 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34.17 2
PY2020 $83.58 5
PY2021 $95.63 5
PY2022 $125.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $978,346.35 79
PY2024 Principal investigator $750,186.73 535
PY2023 Recipient $250.00 1
PY2023 Principal investigator $1,161,263.89 753
PY2022 Recipient $450.00 1
PY2022 Principal investigator $433,849.06 425
PY2021 Recipient $437.46 1
PY2021 Principal investigator $229,625.48 182
PY2020 Principal investigator $282,764.54 64
PY2019 Principal investigator $543,958.67 209

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $17,570.00 12/22/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175335439
Principal investigator 1 Janssen Research & Development, LLC $81,527.00 12/18/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175335399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $565.50 12/17/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518509
Principal investigator 1 Alnylam Pharmaceuticals Inc. $400.00 12/17/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518513
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,370.60 12/17/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518516
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,270.70 12/01/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518521
Principal investigator 1 Janssen Research & Development, LLC $33,557.00 11/28/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175335585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $514.80 11/07/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518497
Principal investigator 1 Alnylam Pharmaceuticals Inc. $400.00 11/07/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518502
Principal investigator 1 Alnylam Pharmaceuticals Inc. $209.30 11/07/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518504
Principal investigator 1 Janssen Research & Development, LLC $1,256.00 11/07/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175335530
Principal investigator 1 Janssen Research & Development, LLC $1,256.00 11/07/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175335659
Principal investigator 1 Janssen Research & Development, LLC $33,650.00 10/30/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175335570
Principal investigator 1 Janssen Research & Development, LLC $38,411.00 10/27/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175335736
Principal investigator 1 Alnylam Pharmaceuticals Inc. $20,598.43 10/24/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518525
Principal investigator 1 Eli Lilly and Company $25,456.00 10/08/2025 Non-covered Recipient Entity
IVAM CLINICAL AND INVESTIGATIO
AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187885006
Principal investigator 1 Janssen Research & Development, LLC $20,000.00 09/29/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175335423
Principal investigator 1 Janssen Research & Development, LLC $10,494.00 09/29/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175335605
Principal investigator 1 Janssen Research & Development, LLC $11,915.00 09/26/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335499
Principal investigator 1 Janssen Research & Development, LLC $18,698.00 09/26/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175335578
Principal investigator 1 Janssen Research & Development, LLC $25,589.00 09/25/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335562
Principal investigator 1 Alnylam Pharmaceuticals Inc. $418.60 09/10/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $209.30 09/05/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518402
Principal investigator 1 Janssen Research & Development, LLC $17,922.00 09/05/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175335683
Principal investigator 1 Janssen Research & Development, LLC $38,307.00 09/01/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335490
Principal investigator 1 Janssen Research & Development, LLC $7,797.00 08/25/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175335431
Principal investigator 1 Janssen Research & Development, LLC $1,264.00 08/25/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175335482
Principal investigator 1 Janssen Research & Development, LLC $386.00 08/18/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335410
Principal investigator 1 Janssen Research & Development, LLC $17,700.00 08/18/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335506
Principal investigator 1 AstraZeneca UK Limited $9,357.40 08/06/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185540747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $797.00 08/01/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518405
Principal investigator 1 Janssen Research & Development, LLC $23,872.00 07/28/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335514
Principal investigator 1 Alnylam Pharmaceuticals Inc. $14,754.06 07/16/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518412
Principal investigator 1 Alnylam Pharmaceuticals Inc. $897.00 07/14/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518422
Principal investigator 1 Alnylam Pharmaceuticals Inc. $62,432.80 07/14/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518426
Principal investigator 1 Alnylam Pharmaceuticals Inc. $897.00 07/14/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518463
Principal investigator 1 Janssen Research & Development, LLC $27,474.00 07/07/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335614
Principal investigator 1 Alnylam Pharmaceuticals Inc. $54,432.00 07/02/2025 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518418
Principal investigator 1 Janssen Research & Development, LLC $766.00 06/30/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175335668
Principal investigator 1 Janssen Research & Development, LLC $1,417.00 06/30/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175335726
Principal investigator 1 Janssen Research & Development, LLC $1,058.00 06/02/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335392
Principal investigator 1 Janssen Research & Development, LLC $8,451.00 06/02/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335472
Principal investigator 1 Janssen Research & Development, LLC $500.00 05/30/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335551
Principal investigator 1 Janssen Research & Development, LLC $17,095.00 05/29/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335706
Principal investigator 1 Janssen Research & Development, LLC $7,797.00 05/05/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175335416
Principal investigator 1 Janssen Research & Development, LLC $3,165.00 05/05/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175335446
Principal investigator 1 Janssen Research & Development, LLC $3,165.00 05/05/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175335454
Principal investigator 1 Janssen Research & Development, LLC $6,528.00 05/05/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335675
Principal investigator 1 Janssen Research & Development, LLC $98.00 05/05/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335716
Principal investigator 1 Janssen Research & Development, LLC $7,545.00 04/28/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335523
Principal investigator 1 Janssen Research & Development, LLC $10,695.00 04/23/2025 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175197229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $54,186.16 04/16/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518393
Principal investigator 1 Janssen Research & Development, LLC $1,264.00 04/14/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175335591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 04/11/2025 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518364
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,001.00 04/11/2025 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518372
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 04/11/2025 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518374
Principal investigator 1 Alnylam Pharmaceuticals Inc. $400.00 04/09/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $418.60 04/09/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518385
Principal investigator 1 Alnylam Pharmaceuticals Inc. $150.00 04/09/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518389
Principal investigator 1 Janssen Research & Development, LLC $507.00 04/09/2025 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1175196315
Principal investigator 1 Janssen Research & Development, LLC $14,297.00 04/02/2025 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175194643
Principal investigator 1 Janssen Research & Development, LLC $6,955.00 04/02/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335536
Principal investigator 1 Janssen Research & Development, LLC $2,950.00 04/02/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335622
Principal investigator 1 Janssen Research & Development, LLC $98.00 04/02/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335631
Principal investigator 1 Janssen Research & Development, LLC $16,676.00 03/28/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335597
Principal investigator 1 Janssen Research & Development, LLC $9,478.00 03/14/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335690
Principal investigator 1 Janssen Research & Development, LLC $148.00 03/05/2025 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1175196692
Principal investigator 1 Alnylam Pharmaceuticals Inc. $846.00 03/03/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $183.00 03/03/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518319
Principal investigator 1 Janssen Research & Development, LLC $17,315.00 03/03/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335696
Principal investigator 1 Janssen Research & Development, LLC $11,997.00 02/24/2025 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175194774
Principal investigator 1 Alnylam Pharmaceuticals Inc. $19,240.10 02/21/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68,488.00 02/21/2025 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215518331
Principal investigator 1 Janssen Research & Development, LLC $3,357.00 02/17/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335464
Principal investigator 1 Janssen Research & Development, LLC $230.00 02/14/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335647
Principal investigator 1 Janssen Research & Development, LLC $28,488.00 01/31/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335543
Principal investigator 1 Janssen Research & Development, LLC $2,945.00 01/27/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175335639
Principal investigator 1 Janssen Research & Development, LLC $12,409.00 01/24/2025 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175196000
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,914.00 01/15/2025 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185540745